Amenorrhea News and Research

RSS

Amenorrhea is the absence of a menstrual period. Primary amenorrhea is when a young woman has not yet had a period by age 16. Secondary amenorrhea describes someone who used to have a regular period but then it stopped for at least three months (this can include pregnancy).

Incorporating postpartum contraceptive services across the continuum of reproductive healthcare

Approximately one-quarter of inter-birth intervals in low- and middle-income countries are less than 24 months in length, exposing infants to risks of prematurity, low birthweight, and death. Increased evidence of these health risks has emerged in the past few decades and, after a period of neglect, interest in postpartum family planning has followed, supported by organizations like WHO and USAID.

13 Dec 2015

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

25 Jul 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Childhood macroprolactinomas amenable to dopamine agonist treatment

Dopamine agonist treatment normalises prolactin levels in about three-quarters of children with macroprolactinomas, show findings from a large series.

30 Jan 2015

Scientists find that blocking hormone reduces stress-induced infertility in female rats

University of California, Berkeley, scientists have discovered that chronic stress activates a hormone that reduces fertility long after the stress has ended, and that blocking this hormone returns female reproductive behavior to normal.

13 Jan 2015

The Female Athlete Triad: A medical condition in active girls and women

Sophie is a 15 year old cross country runner who has a history of a foot stress fracture and shin splints. Often she does not eat prior to her workouts.

17 Oct 2014

New guidelines on management and return to play of Female Athlete Triad discussed at AMSSM

The Female Athlete Triad is a medical condition often observed in physically active girls and women, and involves three components: low energy availability with or without disordered eating, menstrual dysfunction and low bone mineral density.

15 Apr 2014

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013.

4 Mar 2014

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women.

24 Jan 2014

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

14 Dec 2013

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Women diagnosed for menopause after breast cancer may vary with type of doctors

Hormonal treatment for breast cancer causes menopause in over 80% of women in the first year of therapy, but now new research, published in the peer-reviewed journal Climacteric, has found that how these women are diagnosed and treated for menopausal symptoms can vary substantially according to which type of doctor a woman sees.

13 Aug 2013

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

GnRH agonist may protect breast cancer patient fertility

Treatment with a gonadotropin-releasing hormone agonist may reduce the risk for chemotherapy-induced amenorrhea, research shows.

1 Oct 2012

IOF review outlines pathophysiology, diagnosis and management of osteoporosis in young adults

Much of the research defining osteoporosis and fracture risk has focused on older adults, i.e. postmenopausal women and men over the age of 50. While older adults are at highest risk of osteoporosis and related fractures, the disease can also affect younger adults between 20 and 50 years of age. However, the diagnosis and management of osteoporosis in young adults is complicated by special challenges, including a complex pathophysiology and the related fact that there is no clear definition of osteoporosis, or of intervention thresholds, in this age group.

20 Jun 2012

Study finds some possible shortfalls in screening methods for female athlete triad

Female athletes, particularly those involved in high level college sports at the NCAA Division I level, are particularly prone to a trio of medical issues called the "female athlete triad." A new study conducted by sports medicine researchers at the Medical College of Wisconsin found there are some possible shortfalls in the methods used to screen these athletes for the triad, and that could put athletes at risk for lifelong health problems.

7 Jun 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

Watson introduces generic PROMETRIUM for endometrial hyperplasia

Watson Pharmaceuticals, Inc. today confirmed that Watson has launched an authorized generic version of PROMETRIUM (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories.

2 Mar 2012